Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 462
- Registration Number
- NCT03742297
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitario de Cruces, Bilbao, Spain
🇪🇸Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 250
- Registration Number
- NCT03729804
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-11-01
- Target Recruit Count
- 58
- Registration Number
- NCT03673826
- Locations
- 🇮🇹
IT-Roma-SAPIENZA, Roma, Italy
🇳🇱NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp, Netherlands
🇨🇿CZ-Brno-UHBRNO, Brno, Czechia
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03606577
- Locations
- 🇫🇷
CHRU Hôpital du Haut Lévêque, Pessac, France
🇫🇷CHRU - Hôpital de Pontchaillou, Rennes, France
🇫🇷CH de Lyon Sud, Lyon, France
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Emory University
- Target Recruit Count
- 23
- Registration Number
- NCT03605719
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT03556332
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Wake Forest University (Data Collection Only), Winston-Salem, North Carolina, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 177
- Registration Number
- NCT03530683
- Locations
- 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
- Conditions
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7
- Registration Number
- NCT03512353
- Locations
- 🇺🇸
Research Site, Yakima, Washington, United States
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 75
- Registration Number
- NCT03500445
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.